Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
Data from Tykerb investigational phase III studies in neo-adjuvant HER2-positive breast cancer presented at breast cancer symposium
Topline results were presented today from two Phase III studies examining the effect of Tykerb (lapatinib) in the neo-adjuvant setting of HER2-positive breast cancer.i, ii The c...
Read more -
GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals in China
GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 ...
Read more -
GlaxoSmithKline and Human Genome Sciences announce FDA extension of Benlysta® PDUFA target date to 10th March 2011
GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User...
Read more -
Avodart reviewed by FDA advisory committee for prostate cancer risk reduction
GlaxoSmithKline (NYSE: GSK) today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplementa...
Read more -
GSK and Valeant announce receipt of U.S. FDA Complete Response letter for ezogabine
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced receipt of a Complete Response letter from the U.S. Food and Drug Administr...
Read more -
Government patent box proposals ‘transform’ UK attractiveness for investment
GSK welcomes the publication today of the Governments proposals to establish a patent box. The measure is designed to encourage investment in R&D and related manufacturing ...
Read more -
GlaxoSmithKline to increase its shareholding in Theravance
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) (the “Company”) announced today that GSK will increase its shareholding in Theravance through the purch...
Read more -
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia
GlaxoSmithKline (GSK) and JSC Binnopharm (Binnopharm) today announced an alliance to enable the local secondary manufacture of a number of GSK vaccines in Russia. The agreement ...
Read more -
Human Genome Sciences and GlaxoSmithKline announce vote of FDA advisory committee to recommend approval of Benlysta® for systemic lupus erythematosus
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) ha...
Read more -
New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients
Findings from a new study show, compared to placebo, treatment with high-dose prescription omega-3 fatty acids did not reduce the recurrence of symptomatic atrial fibrillation (...
Read more -
GlaxoSmithKline and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases
GlaxoSmithKline and the Oswald Cruz Foundation (Fiocruz) have today announced a unique collaboration to research and develop new and innovative medicines to treat diseases which...
Read more -
GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal
GlaxoSmithKline (GSK) announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag) for the treatment of the blood ...
Read more -
GSK and Amicus Therapeutics enter exclusive worldwide agreement to develop and commercialise Amigal™ for Fabry disease
GlaxoSmithKline (GSK) and Amicus Therapeutics (Amicus) today announced a definitive agreement to develop and commercialise AmigalTM (migalastat HCl), currently in Phase 3 for th...
Read more -
GSK completes previously reported settlement with U.S. Department of Justice regarding former manufacturing plant
GlaxoSmithKline today announced that it has finalized a previously reported agreement in principle with the U.S. Attorneys Office for the District of Massachusetts and the U.S....
Read more -
GSK announces Q3 results for 2010
Q3 EPS before major restructuring of 28.2p
Read more -
GSK outlines approach to delivering advances in the treatment of rare diseases
Creating an environment that fosters innovation, intuition and scientific acumen to deliver breakthrough thinking and new medicines
Read more -
GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases
GlaxoSmithKline PLC (GSK), Fondazione Telethon and Fondazione San Raffaele today announced a new strategic alliance to research and develop novel treatments to address rare gene...
Read more -
GSK increases support for WHO strategy to improve children’s health with new 5-year commitment to expand donations of albendazole medicine
At the launch of the World Health Organizations (WHO) first report on Neglected Tropical Diseases today, GSK announced a new five year commitment to expand the donation of its m...
Read more -
GSK takes minority stake in newly formed Convergence Pharmaceuticals
GlaxoSmithKline plc (GSK) today announced that it has taken an 18% minority equity stake in Convergence Pharmaceuticals Limited, a new biotechnology company that will focus on t...
Read more -
GSK provides update on Herpevac trial for women evaluating Simplirix™ (Herpes Simplex Vaccine)
GlaxoSmithKline (GSK) has made the decision not to pursue further worldwide development of Simplirix™ (Herpes Simplex Vaccine), an experimental vaccine intended to prevent...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
